Skip to main content

Table 2 ADRs of bDMARDs in patients with JIA, JSLE and JDM

From: Adverse drug reactions associated with treatment in patients with chronic rheumatic diseases in childhood: a retrospective real life review of a single center cohort

  Medications
ETN ADA IFX TCZ ABA RTX TOTAL
Patients on MED 54 49 36 9 7 10 165
Patients on MED with ADR 10 6 11 2 1 30
Patients on MED with ADR(%) 18.5 12.2 30.5 22.2 10 18.2
Infections 1 1 2
Blood and lymphatic system disorders:
 - Thrombocytopenia 1 1
Nervous system disorders:
 - Headache/dizziness/discomfort 1 1
Eye disorders:
 - Uveitis 2 1 3
Gastrointestinal disorders:
 - Nausea/vomiting 2 3 1 6
 - Epigastric pain 1 1
Hepatobiliary disorders:
 -↑ liver enzymes 1 1
Skin and subcutaneous tissue disorders:
 - Atopic dermatitis 1 1
 - Psoriasis 1 1
 - Urticaria 3 1 4
Renal and urinary disorders:
 - Nephritis 1 1
 - Hematuria 1 1
General disorders and administration site conditions:
 - Anaphylaxis 2 2
 - Local reactions and pain 5 1 2 8
Total number of ADRs 11 8 11 2 1 33
  1. ADR - adverse drug reaction, JIA - juvenile idiopathic arthritis, JSLE - juvenile systemic lupus erythematosus, JDM - juvenile dermatomyositis, MED - Medication. Patients on MED- number of patients who used the medication. Patients on MED with ADR- number of patients who used the medication and experienced at least one adverse drug reaction. Patients on MED with ADR(%)- percentage of patients who used the medication and experienced at least one adverse drug reaction = N. P with ADR X 100/N.P on MED. ↑ liver enzymes - elevated liver enzymes. ETN - etanercept (median dose - 1.1 mg/kg/week and median length of treatment - 8.4 months). ADA - adalimumab (median dose - 0.8 mg/kg/dose every 15 days and median length of treatment - 11 months). IFX - infliximab (median dose - 5.4 mg/kg/dose every 8 weeks and median length of treatment - 8.4 months). TCZ - tocilizumab (median dose - 9.7 mg/kg/dose monthly and median length of treatment - 7.5 months). ABA - abatacept (median dose - 10 mg/kg/dose monthly and median length of treatment - 12 months). RTX - rituximab (median dose 1 g/dose twice monthly every 6 months)